| Basics |
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
|
| IPO Date: |
December 22, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$13.23B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.89 | 1.98%
|
| Avg Daily Range (30 D): |
$1.22 | 1.66%
|
| Avg Daily Range (90 D): |
$0.98 | 1.64%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.19M |
| Avg Daily Volume (30 D): |
2.46M |
| Avg Daily Volume (90 D): |
2.27M |
| Trade Size |
| Avg Trade Size (Sh.): |
83 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
67 |
| Institutional Trades |
| Total Inst.Trades: |
11,404 |
| Avg Inst. Trade: |
$2.71M |
| Avg Inst. Trade (30 D): |
$4.85M |
| Avg Inst. Trade (90 D): |
$4.42M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.39M |
| Avg Closing Trade (30 D): |
$21.32M |
| Avg Closing Trade (90 D): |
$19.13M |
| Avg Closing Volume: |
142.63K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.61
|
$-.8
|
$.78
|
|
Diluted EPS
|
$-1.61
|
$-.8
|
$.7
|
|
Revenue
|
$ 966.96M
|
$ 156.72M
|
$ 452.05M
|
|
Gross Profit
|
$ 955.18M
|
$ 154.38M
|
$ 447.9M
|
|
Net Income / Loss
|
$ -256.34M
|
$ -128.61M
|
$ 123.55M
|
|
Operating Income / Loss
|
$ -278.05M
|
$ -160.18M
|
$ 139.82M
|
|
Cost of Revenue
|
$ 11.78M
|
$ 2.34M
|
$ 4.15M
|
|
Net Cash Flow
|
$ 3.48M
|
$ 41.12M
|
$ 32.52M
|
|
PE Ratio
|
|
|
|
|
|
|
